The longstanding view has been that insomnia, and other forms of sleep disturbance, emerge as a consequence of dementia and are the result of progressive neuronal damage. However, there is growing evidence that the direction of causation may go both ways, with sleep disturbance potentially increasing vulnerability to dementia. Longitudinal studies have found that sleep disturbance often precedes and increases risk for dementia by several years.The purpose of this study is to examine the relationship between chronic insomnia and dementia biomarkers and orexin levels found in cerebrospinal fluid (CSF).
Fifteen adults age 30-50 with chronic insomnia will undergo overnight polysomnography and CSF sampling in the morning as part of protocol number 829221 (may viewed here: https://clinicalresearch.itmat.upenn.edu/clinicaltrial/5995/dementia-insomnia-chronic-insomnia-and-csf-markers-of-dementia/).
Participants who wish to enroll in phase 2 must first have been enrolled in phase 1 linked above.
Cognitive behavioral therapy for insomnia (CBT-I) has been the ‘gold standard’ for the treatment of insomnia. Subjects who enroll in phase 2 will receive 6-8 sessions of CBT-I over a 6-8 week timeframe prior to completing a second overnight PSG and and CSF sampling in the morning (again, described in the previous protocol which may be viewed here: https://clinicalresearch.itmat.upenn.edu/clinicaltrial/5995/dementia-insomnia-chronic-insomnia-and-csf-markers-of-dementia/).
Study Identifier: 833798
Contact the research team to learn more about this study.